Weekly Digest - June 2025

Weekly Digest - June 2025

18 June 2025: IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan initiated in patients with pretreated metastatic castration-resistant prostate cancer

  • The IDeate-Prostate01 Phase 3 trial has begun, evaluating Ifinatamab deruxtecan (I-DXd) vs Docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on androgen receptor pathway inhibitors
  • The trial is based on promising early-phase results from the IDeate-PanTumor01 study, which showed antitumor activity in heavily pretreated mCRPC patients
  • Ifinatamab deruxtecan is a B7-H3 directed DXd ADC developed by Daiichi Sankyo and Merck, aiming to become a first-in-class treatment for mCRPC

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home